MayTech Global Investments LLC raised its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 48.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 377,752 shares of the company's stock after acquiring an additional 123,200 shares during the quarter. Novo Nordisk A/S makes up 3.8% of MayTech Global Investments LLC's investment portfolio, making the stock its 12th largest position. MayTech Global Investments LLC's holdings in Novo Nordisk A/S were worth $32,494,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of NVO. Center for Financial Planning Inc. grew its stake in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after buying an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL raised its position in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares during the last quarter. Transce3nd LLC bought a new position in Novo Nordisk A/S during the 4th quarter valued at about $33,000. Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Novo Nordisk A/S in the fourth quarter worth approximately $39,000. Finally, Albion Financial Group UT grew its position in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after purchasing an additional 278 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.
Novo Nordisk A/S Price Performance
NYSE:NVO opened at $67.70 on Tuesday. The firm has a market capitalization of $303.79 billion, a price-to-earnings ratio of 20.58, a PEG ratio of 0.90 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The business has a 50 day simple moving average of $68.75 and a 200-day simple moving average of $85.51. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $79.17 billion. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the stock. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating for the company. Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Finally, Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Moderate Buy" and an average price target of $135.00.
View Our Latest Stock Report on NVO
Novo Nordisk A/S Company Profile
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Further Reading
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
